Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

NICE expands positive recommendation for Erbitux as first-line treatment for RAS wild-type mCRC

pharmaasiaMarch 16, 2017

Tag: NICE , Merck

PharmaSources Customer Service